The FDA approved Dupixent (dupilumab) for bullous pemphigoid (BP) in adults. This approval is based on positive results from a pivotal trial showing improvements in sustained disease remission, itch reduction, and reduced oral corticosteroid use compared to placebo. BP, a rare skin disease primarily affecting the elderly, is characterized by painful blisters, intense itching, and lesions.
This approval is a significant advancement for BP patients, who often face limited and burdensome treatment options. Current therapies often involve systemic corticosteroids, which can have significant side effects, especially for the elderly population typically affected by BP. Dupixent offers a targeted approach to managing the disease, addressing the underlying type 2 inflammation that drives BP. This targeted mechanism offers the potential for improved disease management and a reduction in reliance on systemic corticosteroids, which can lead to a better quality of life for these patients.
In the pivotal ADEPT trial, Dupixent demonstrated a substantial increase in sustained disease remission (18.3% vs. 6.1% for placebo) at 36 weeks. It also showed a significant reduction in itch and a lower cumulative dose of oral corticosteroids. The most common adverse events observed with Dupixent included arthralgia, conjunctivitis, blurred vision, herpes viral infections, and keratitis. One case of acute generalized exanthematous pustulosis was reported in a patient receiving Dupixent.
This FDA approval marks an expansion of Dupixent’s use, adding to its existing approvals for a range of diseases involving type 2 inflammation. This continued expansion reinforces Dupixent’s established safety profile across various age groups and disease areas. The approval offers a new and potentially more effective treatment option for BP patients, suggesting a positive shift in the management of this debilitating disease. The ongoing global regulatory reviews further underscore the potential for Dupixent to impact BP treatment worldwide.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
